What's in UPECLIN HC FM Botucatu Unesp's pipeline?

UPECLIN HC FM Botucatu Unesp has 8 drugs in our index: 4 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 3 in Phase 1.

Which companies overlap with UPECLIN HC FM Botucatu Unesp's portfolio?

Top competitors by shared drug class: Boston Scientific Corporation, Chinese University of Hong Kong, Gulab Devi Hospital, Imperial College London, Juan A. Arnaiz.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/upeclin-hc-fm-botucatu-unesp.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

UPECLIN HC FM Botucatu Unesp — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

UPECLIN HC FM Botucatu Unesp pipeline: 4 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 0 Phase 3 1 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Comparison of two anesthetic drugs	Comparison of two anesthetic drugs	marketed
First-line Antiretroviral Therapy	First-line Antiretroviral Therapy	marketed	Antiretroviral combination therapy (NRTI/NNRTI/PI/INSTI)	HIV reverse transcriptase, HIV protease, HIV integrase (depending on regimen components)	Infectious Disease / Virology
ceftriaxone/oxacillin	ceftriaxone/oxacillin	marketed	Beta-lactam antibiotic combination	Penicillin-binding proteins (PBPs)	Infectious Disease
Polidocanol with Glucose	Polidocanol with Glucose	marketed	Sclerosing agent		Vascular/Dermatology

Therapeutic area mix

Infectious Disease · 1
Infectious Disease / Virology · 1
Vascular/Dermatology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Boston Scientific Corporation · 1 shared drug class
Chinese University of Hong Kong · 1 shared drug class
Gulab Devi Hospital · 1 shared drug class
Imperial College London · 1 shared drug class
Juan A. Arnaiz · 1 shared drug class
Medical University of Vienna · 1 shared drug class
Memorial Healthcare System · 1 shared drug class
National University of Singapore · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for UPECLIN HC FM Botucatu Unesp:

Cite this brief

Drug Landscape (2026). UPECLIN HC FM Botucatu Unesp — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/upeclin-hc-fm-botucatu-unesp. Accessed 2026-05-16.